Figure 2.

Neutrophil‐platelet (PLT) aggregates enhance the generation of NETs in symptomatic patients. (A) Neutrophil‐platelet aggregates from healthy subjects (n = 5), symptomatic patients (n = 5), and asymptomatic patients (n = 5), defined as CD41/CD66b ⁺ events, were detected using flow cytometry. (B) The rate of neutrophil‐platelet aggregates from each group. (C) NETting neutrophils defined as MPO + /citH3+ events were detected from neutrophils isolated from healthy subjects (n = 5), symptomatic patients (n = 5), and asymptomatic patients (n = 5) then analyzed through flow cytometry. (D) The rate of NETting neutrophils from each group. (E) The rate of PS + platelets and (F) CD62P + platelets from each group. (G) Control neutrophils were treated with control PLTs, platelets from asymptomatic patients and platelets from symptomatic patients. In the inhibition assays, treated neutrophils were incubated with platelets from symptomatic patients, in the presence of anti‐CD62P and CD162 antibodies. MPO‐DNA of patients was detected through ELISA and the generation of NETs (arrow) was stained with DAPI. The inset scale bars in I are 30 μm. Data are presented as the mean ± SD. DAPI, 4',6‐diamidino‐2‐phenylindole; ELISA, enzyme‐linked immunosorbent assay; MPO‐DNA, myeloperoxidase‐DNA; NET, neutrophil extracellular traps; PS, phosphatidylserine. *p < .05, **p < .01, ***p < .001 and ****p < .0001